May 15, 2020 at 9:00 AM to 10:00 AM
|Provider||New York AGD Learning Center|
|Speaker||Kenneth E. Fleisher, DDS, FACS|
This case-based presentation will review evidence-based data that has led to paradigm shifts for pathogenesis and innovative strategies for risk assessment, prevention and management of MRONJ.
The New York AGD Learning Center Presents
"Update on Medication Related Osteonecrosis of the Jaw"
Date: Friday, May 15, 2020
Course 9:00am to 10:0am
Course Code: 310
Presentation by: Kenneth E. Fleisher, DDS, FACS
Kenneth Fleisher, DDS, FACS is a board certified oral and maxillofacial surgeon. He is a Clinical Associate Professor in the Department of Oral and Maxillofacial Surgery at the New York University College of Dentistry, Associate Director of the OMS Postgraduate training program and an attending surgeon Bellevue Hospital Center and New York University Langone Medical Center in Plastic Surgery where he participates training pre-doctoral dental students, postgraduate residents, international postgraduate students and faculty on the advancements related to understanding Medication-related osteonecrosis of the jaw (MRONJ).
Course Goals and Objectives:
Bone health and maintenance of bone integrity are important concerns during comprehensive cancer care and management of osteoporosis. Bisphosphonates and denosumab are antiresorptive medications widely used for the prevention and treatment of osteoporosis and skeletal complications associated with metastatic cancer and multiple myeloma. Medication-related osteonecrosis of the jaw (MRONJ) related to antiresorptive therapy is a condition that has created numerous dilemmas in patient management and may have a broad health impact.
The participant will learn:
- Strategies for diagnosis of MRONJ related to clinical presentation, imaging and differential diagnosis.
- Risk assessment for dental treatment: What works and what doesn’t.
- Recent advances in pathogenesis: What we know today and how this may impact clinical decisions.
- Strategies for improving oral health via dentoalveolar surgery, restorative dentistry and implant surgery.
- Management options for patients with MRONJ.
New York AGD is designated as an Approved PACE Program Provider by the Academy of General Dentistry. The formal continuing education programs of this program provider are accepted by AGD for Fellowship, Mastership and membership maintenance credit. Approval does not imply acceptance by a state or provincial board of dentistry or AGD endorsement. The current term of approval extends from 01/01/2019 to 12/31/2020. Provider ID # 219318